

1 Risk factors mediating the effect of body-mass index and 2 waist-to-hip ratio on cardiovascular outcomes: Mendelian 3 randomization analysis

4 5 Short title: Cardiometabolic mediators of obesity 6

7 Dipender Gill BMBCh PhD¹, Verena Zuber PhD^{1,2}, Jesse Dawson MBChB PhD³, Jonathan Pearson-
8 Stuttard BMBCh^{1,4}, Alice R. Carter MSc^{5,6}, Eleanor Sanderson PhD^{5,6}, Ville Karhunen MSc¹, Michael G.
9 Levin MD⁷⁻⁹, Robyn E. Wootton PhD^{5,10,11}, VA Million Veteran Program, Derek Klarin MD¹²⁻¹⁵, Philip S.
10 Tsao PhD^{16,17}, Konstantinos K. Tsilidis PhD^{1,18}, Scott M. Damrauer MD^{9,19}, Stephen Burgess PhD^{2,20},
11 Paul Elliott FMedSci^{1,4,21-23}

12 13 Affiliations

14 ¹Department of Epidemiology and Biostatistics, School of Public Health, Imperial College London,
15 London, UK.

16 ²Medical Research Council Biostatistics Unit, Cambridge Institute of Public Health, Cambridge, UK.

17 ³University of Glasgow, Institute of Cardiovascular and Medical Sciences, Glasgow, UK.

18 ⁴School of Public Health, Medical Research Council-Public Health England Centre for Environment
19 and Health, Imperial College London, London, United Kingdom

20 ⁵Medical Research Council Integrative Epidemiology Unit, University of Bristol, Bristol, UK.

21 ⁶Population Health Sciences, Bristol Medical School, University of Bristol, Bristol, UK.

22 ⁷Division of Cardiovascular Medicine, University of Pennsylvania Perelman School of
23 Medicine, Pennsylvania, USA.

- 24 ⁸Department of Medicine, University of Pennsylvania Perelman School of Medicine, Pennsylvania,
25 USA.
- 26 ⁹Corporal Michael J. Crescenzi VA Medical Center, Pennsylvania, USA.
- 27 ¹⁰School of Psychological Science, University of Bristol, Bristol, UK.
- 28 ¹¹National Institute for Health Research Biomedical Research Centre, University Hospitals Bristol NHS
29 Foundation Trust and the University of Bristol, Bristol, UK.
- 30 ¹²Malcom Randall VA Medical Center, Gainesville, Florida, USA.
- 31 ¹³Center for Genomic Medicine, Massachusetts General Hospital, Harvard Medical School,
32 Massachusetts, USA.
- 33 ¹⁴Program in Medical and Population Genetics, Broad Institute of MIT and Harvard, Massachusetts,
34 USA.
- 35 ¹⁵Division of Vascular Surgery and Endovascular Therapy, University of Florida School of Medicine,
36 Gainesville, Florida, USA.
- 37 ¹⁶VA Palo Alto Health Care System, California, USA.
- 38 ¹⁷Department of Medicine, Stanford University School of Medicine, California, USA.
- 39 ¹⁸Department of Hygiene and Epidemiology, University of Ioannina Medical School, Ioannina,
40 Greece.
- 41 ¹⁹Department of Surgery, University of Pennsylvania Perelman School of Medicine, Philadelphia,
42 USA.
- 43 ²⁰Cardiovascular Epidemiology Unit, Department of Public Health and Primary Care, University of
44 Cambridge, Cambridge, UK.
- 45 ²¹UK Dementia Research Institute at Imperial College London, London, UK.
- 46 ²²Imperial Biomedical Research Centre, Imperial College London and Imperial College NHS
47 Healthcare Trust, London, UK.
- 48 ²³Health Data Research UK-London, London, UK.
- 49

50 **Corresponding author**

51 Dr Dipender Gill

52 Address: Department of Epidemiology and Biostatistics, School of Public Health, Medical School

53 Building, St Mary's Hospital, Norfolk Place, Imperial College London, W2 1PG, United Kingdom

54 Telephone: +44 (0) 7904843810

55 E-mail: dipender.gill@imperial.ac.uk

56

57 **Word count**

58 2 862

59 Abstract

60 **Background:** Higher body-mass index (BMI) and waist-to-hip ratio (WHR) increase the risk of
61 cardiovascular disease, but the extent to which this is mediated by blood pressure, diabetes, lipid
62 traits and smoking is not fully understood.

63 **Methods:** Using consortia and UK Biobank genetic association summary data from 140,595 to
64 898,130 participants predominantly of European ancestry, MR mediation analysis was performed to
65 investigate the degree to which genetically predicted systolic blood pressure (SBP), diabetes, lipid
66 traits and smoking mediated an effect of genetically predicted BMI and WHR on risk of coronary
67 artery disease (CAD), peripheral artery disease (PAD) and stroke.

68 **Results:** The 49% (95% confidence interval [CI] 39%-60%) increased risk of CAD conferred per 1-
69 standard deviation increase in genetically predicted BMI attenuated to 34% (95% CI 24%-45%) after
70 adjusting for genetically predicted SBP, to 27% (95% CI 17%-37%) after adjusting for genetically
71 predicted diabetes, to 47% (95% CI 36%-59%) after adjusting for genetically predicted lipids, and to
72 46% (95% CI 34%-58%) after adjusting for genetically predicted smoking. Adjusting for all the
73 mediators together, the increased risk attenuated to 14% (95% CI 4%-26%). A similar pattern of
74 attenuation was observed when considering genetically predicted WHR as the exposure, and PAD or
75 stroke as the outcomes.

76 **Conclusions:** Measures to reduce obesity will lower risk of cardiovascular disease primarily by
77 impacting on downstream metabolic risk factors, particularly diabetes and hypertension. Reduction
78 of obesity prevalence alongside control and management of its mediators is likely to be most
79 effective for minimizing the burden of obesity.

80 Background

81 Cardiovascular disease (CVD) is the leading cause of death and disability worldwide(1). Obesity can
 82 contribute towards CVD risk through effects on hyperglycaemia, hypertension, dyslipidaemia, and
 83 smoking behaviour(2-5). The global prevalence of obesity has more than tripled in the last 40 years,
 84 with an even greater rise in incidence amongst children(6). It is estimated that by 2030,
 85 approximately half of the US population will be obese(7). There are treatments available to
 86 effectively manage the downstream mediators through which obesity causes CVD(8-11).
 87 Understanding of such pathways is therefore paramount to reducing cardiovascular risk.

88 Obesity can be measured by various means, and is often defined as a body-mass index (BMI) of
 89 greater than 30kg/m² (12). However, BMI is a not a direct measure of adiposity, and is also
 90 correlated with fat-free mass(12). Assessment of obesity using waist-to-hip ratio (WHR) is less
 91 subject to influence from height and muscle mass, and is associated with cardiovascular risk in
 92 individuals with a normal BMI(13, 14). Both BMI and WHR are easy to measure clinically, without any
 93 requirement for radiological investigation. Conventional observational studies have shown that the
 94 relationship between obesity measures such as BMI and WHR with CVD is attenuated when
 95 adjustment is made for cardiometabolic risk factors such as blood pressure, lipid traits or measures
 96 of glycaemia(15). This has allowed for estimation of the proportion of the effect of obesity that is
 97 mediated through these intermediates(15). However, such analysis is vulnerable to bias from
 98 confounding and measurement error, both of which can result in underestimation of the proportion
 99 of effect mediated(16, 17). The Mendelian randomization (MR) approach uses genetic variants as
 100 instruments for studying the effect of an exposure on an outcome, and has now been extended to
 101 perform mediation analyses(16, 18). The use of randomly allocated genetic variants in this paradigm
 102 means that the estimates generated are less vulnerable to confounding from environmental factors,
 103 with consideration of their lifelong effects reducing bias from measurement error(16).

The increasing availability of large-scale genome-wide association study (GWAS) data has greatly facilitated MR analyses considering cardiovascular risk factors and outcomes. In this study, we aimed to use such data within the MR framework to investigate the role of blood pressure, diabetes, fasting glucose, lipid traits and smoking in mediating the effect of BMI and WHR respectively on coronary artery disease (CAD), peripheral arterial disease (PAD) and stroke risk.

Methods

Ethical approval, data availability and reporting

The data used in this work are publicly available and the studies from which they were obtained are cited. All these studies obtained relevant participant consent and ethical approval. The results from the analyses performed in this work are presented in the main manuscript or its supplementary files. This paper has been reported based on recommendations by the STROBE-MR Guidelines (Research Checklist)(19). The study protocol and details were not pre-registered.

Data sources

Genetic association estimates for BMI and WHR were obtained from the GIANT Consortium GWAS meta-analysis of 806 834 and 697 734 European-ancestry individuals respectively(20). Genetic association estimates for SBP were obtained from a GWAS of 318 417 White British individuals in the UK Biobank, with correction made for any self-reported anti-hypertensive medication use by adding 10mmHg to the mean SBP measured from two automated recordings that were taken two minutes apart at baseline assessment(21). Genetic association estimates for lifetime smoking (referred to hereon as smoking) were obtained from a GWAS of 462 690 European-ancestry individuals in the UK Biobank(22). A lifetime measure of smoking was created based on self-reported age at initiation, age at cessation and cigarettes smoked per day(22). Genetic association estimates for liability to diabetes came from the DIAGRAM Consortium GWAS meta-analysis of 74 124 cases and 824 006 controls, all of European ancestry(23). Genetic association estimates for plasma fasting glucose were

obtained by using PLINK software to carry out a meta-analysis of MAGIC Consortium GWAS summary data from separate analyses of 67 506 men and 73 089 women who were not diabetic(24, 25). Genetic association estimates for fasting serum low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C) and triglycerides were obtained from the Global Lipids Genetic Consortium GWAS of 188,577 European-ancestry individuals(26). Genetic association estimates for CAD were obtained from the CARDIoGRAMplusC4D Consortium 1000G multi-ethnic GWAS (77% European-ancestry) of 60 801 cases and 123 504 controls(27). Genetic association estimates for PAD were obtained from the Million Veterans Program multi-ethnic (72% European-ancestry) GWAS of 31 307 cases and 211 753 controls(28). Genetic association estimates for stroke were obtained from the MEGASTROKE multi-ethnic (86% European-ancestry) GWAS of 67 162 cases (of any stroke) and 454 450 controls(29). Population characteristics and specific trait definitions relating to all these summary genetic association estimates are available in their original publications. For the analyses performed in this current work, genetic variants from different studies were aligned by their effect alleles and no exclusions were made for palindromic variants. Only variants for which genetic association estimates were available for all the traits being investigated in any given analysis were considered, and proxies were not used.

Instrument selection

To estimate the total effect of BMI and WHR respectively on the considered cardiovascular outcomes, instruments were selected as single-nucleotide polymorphisms (SNPs) that associated with BMI or WHR at genome-wide significance ($P < 5 \times 10^{-8}$) and were in pair-wise linkage disequilibrium (LD) $r^2 < 0.001$. To select instruments for mediation analysis, all SNPs related to the considered exposure (BMI or WHR) or mediators at genome-wide significance were pooled and clumped to pairwise LD $r^2 < 0.001$ based on the lowest P -value for association with any trait. All clumping was performed using the TwoSampleMR package in R(30).

Total effects

Random-effects inverse-variance weighted (IVW) MR was used as the main analysis for estimating the total effects of genetically predicted BMI and genetically predicted WHR respectively on each of the considered CVD outcomes(31). Contamination-mixture method and weighted median MR were used in sensitivity analyses to explore the robustness of the findings to potential pleiotropic effects of the variants(32, 33). The contamination-mixture model makes the assumption that MR estimates from valid instruments follow a normal distribution that centres on the true causal effect estimate, while those calculated from invalid instrument variants follow a normal distribution centred on the null(33). This allows for a likelihood function to be specified and maximized when allocating each variant to one of the two mixture distributions(33). The weighted median approach orders the MR estimates from individual variants by their magnitude weighted for their precision and selects the median as the overall MR estimate, calculating standard error by bootstrapping(32). The MendelianRandomization package in R was used for performing the IVW, contamination-mixture and weighted median MR analyses(34).

Mediation analysis

To estimate the direct effect of genetically predicted BMI and genetically predicted WHR on each of the three considered CVD outcomes that was not being mediated by the investigated intermediary risk factors, summary data multivariable MR was performed(35-37). Specifically, the variant-outcome genetic association estimates were regressed on the variant-exposure and variant-mediator estimates, weighted for the precision of the variant-outcome association, and with the intercept fixed to zero(37). Using this approach, adjustment was made for genetically predicted SBP, diabetes, smoking and lipid traits (LDL-C, HDL-C and triglycerides together) in turn, and finally including all mediators together in a joint model. In a sensitivity analysis, genetically predicted diabetes was excluded from this joint model to remove any bias that might be introduced because of its binary nature(38). For analyses considering genetically predicted fasting glucose in non-diabetics

instead of genetically predicted diabetes, the corresponding genetic association data were substituted.

Multivariable MR mediation analysis was performed to estimate the proportion of the effect of BMI and WHR respectively on CAD, PAD and stroke that was mediated through each of the considered risk factors, and also all of them together(16). Specifically, the direct effect of genetically predicted BMI and genetically predicted WHR respectively was divided by their total effect and subtracted from 1, with standard errors estimated using the propagation of error method(16, 18).

Independent effects of genetically predicted BMI and WHR

The direct effects of genetically predicted BMI and genetically predicted WHR on the considered CVD outcomes that are not mediated through each other were measured by including only these two traits together as exposures in the summary data multivariable MR model described above.

Results

Total effects

Considering total effects, there was consistent evidence across the IVW, contamination-mixture and weighted median MR methods that both higher genetically predicted BMI and higher genetically predicted WHR increased CAD, PAD and stroke risk (Figure 1). In the main IVW MR analysis, the odds ratio (OR) per 1-standard deviation (SD) increase in genetically predicted BMI for CAD risk was 1.49 (95% confidence interval [CI] 1.39-1.60), for PAD risk was 1.70 (95% CI 1.58-1.82), and for stroke risk was 1.22 (95% CI 1.15-1.29). For a 1-SD increase in genetically predicted WHR, this was 1.54 (95% CI 1.38-1.71) for CAD risk, 1.55 (95% CI 1.40-1.71) for PAD risk, and 1.30 (95% CI 1.21-1.40) for stroke risk.

Mediation analysis

There was attenuation in the effect of genetically predicted BMI and genetically predicted WHR on the three CVD outcomes after adjusting for genetically predicted SBP, diabetes, lipid traits (LDL-C, HDL-C and triglycerides together) and smoking, either separately or in the same joint model (Figure 2). The 49% (95% CI 39%-60%) increased risk of CAD conferred per 1-SD increase in genetically predicted BMI attenuated to 34% (95% CI 24%-45%) after adjusting for genetically predicted SBP, to 27% (95% CI 17%-37%) after adjusting for genetically predicted diabetes, to 47% (95% CI 36%-59%) after adjusting for genetically predicted lipids, and to 46% (95% CI 34%-58%) after adjusting for genetically predicted smoking. Adjusting for all the mediators together in the same model, the attenuation was to 14% (95% CI 4% to 26%).

The percentage attenuation in the total effects of genetically predicted BMI and WHR respectively on the three CVD outcomes after adjusting for the mediators is depicted in Supplementary Figure 1. For the effect of genetically predicted BMI on CAD risk, 27% (95% CI 3%-50%) was mediated by genetically predicted SBP, 41% (95% CI 18%-63%) was mediated by genetically predicted diabetes, 3% (-23%-29%) was mediated by genetically predicted lipids, and 6% (95% CI -20%-32%) was mediated by genetically predicted smoking. All the mediators together accounted for 66% (95% CI 42%-91%) of the total effect of genetically predicted BMI on CAD risk.

A joint model including all considered mediators except genetically predicted diabetes was also constructed (Supplementary Figure 2). Adjusting together for all the mediators except genetically predicted diabetes, the effect of genetically predicted BMI on CAD risk attenuated from 49% (95% CI 39%-60%) to 27% (95% CI 16% to 40%).

There was little change in the association of either genetically predicted BMI or genetically predicted WHR with risk of the three CVD outcomes after adjusting for genetically predicted fasting glucose in non-diabetic individuals (Figure 3).

Independent effects of genetically predicted BMI and WHR

Both genetically predicted BMI and genetically predicted WHR had direct effects on CAD, PAD and stroke after mutual adjustment (Figure 4). The increased CAD risk attributed to a 1-SD higher genetically predicted BMI attenuated from 49% (95% CI 39%-60%) to 32% (95% CI 20%-45%) after adjusting for genetically predicted WHR, and the increased CAD risk attributed to a 1-SD higher genetically predicted WHR attenuated from 54% (95% CI 38%-71%) to 33% (95% CI 18%-50%) after adjusting for genetically predicted BMI.

Discussion

This study uses large-scale genetic association data within the MR paradigm to investigate the role of SBP, diabetes, lipid traits and smoking in mediating the effect of BMI and WHR on CAD, PAD and stroke risk. The results support the idea that the majority of the effects of obesity on CVD are mediated through these risk factors, with diabetes and blood pressure being the most notable and accounting for approximately one-third and one-quarter of the effect respectively. In contrast, the analysis of genetically predicted fasting glucose in non-diabetic individuals did not provide any evidence to support its role in mediating the effect of obesity on CVD risk.

The sum of the estimated mediating effects of the various risk factors considered individually was comparable to their total mediating effect estimated when considering them all together in the same model, consistent with them acting through distinct mechanisms. Including genetically predicted BMI and genetically predicted WHR in the same model produced evidence consistent with these traits having direct effects on CVD risk independently of each other. It follows that rather than analysing BMI or WHR alone, they should be considered together as they capture different aspects of adiposity.

Our findings have important clinical and public health implications. Behavioural interventions to reduce obesity can have inadequate long term effects(39), pharmacological treatments may be

limited by unfavourable adverse effect profiles(40), and surgical procedures are often reserved for only severe cases(41). This work supports the concept that the majority of the cardiovascular consequences of obesity may be managed by effectively controlling its downstream mediators, most notably diabetes and raised blood pressure, for which effective pharmacological interventions are available. This has relevance for the more than 640 million individuals worldwide currently living with obesity(42), and the many more forecasted to become obese in coming years(43). Such holistic consideration of obesity together with its mediators could contribute to a shift from the single-disease focus of health systems towards prioritizing multi-morbidity and promoting individual and societal wellness(44). Our analyses were also suggestive of some possible residual effect of BMI and WHR on CVD risk even after adjusting for all the considered mediating risk factors, consistent with metabolically healthy obesity still conferring increased CVD risk(45). Taken together, these results suggest that unless the growing obesity epidemic is effectively tackled, we risk undoing the large reductions in CVD mortality achieved over past decades(1). Population-based approaches that decrease obesity by addressing key upstream drivers such as poor diet and physical inactivity have substantial potential for impact and are also effective for reducing health inequalities(46, 47).

The results of our current study can be contrasted to those from a large-scale observational analysis of 1.8 million people across 97 studies(15, 48). This previous work estimated that 46% (95% CI 42%-50%) of the excess risk conferred by raised BMI on CAD and 76% (95% CI 65%-91%) on stroke were mediated by effects on blood pressure, glucose levels and lipid traits, with blood pressure being the most important and mediation for stroke being greatest(15). However, the approach and data used in our current study offers a number of possible improvements. Our work includes a greater repertoire of risk factors and CVD outcomes than have been considered together previously(15, 49), in particular drawing on recently available GWAS summary data to study smoking and PAD(22, 28). MR analysis uses randomly allocated genetic variants that represent lifelong cumulative liability to the traits for which they serve as instruments and can therefore help overcome the confounding and measurement error that typically bias conventional observational studies(16). Consistent with this,

275 our MR results indicate that these risk factors mediate a greater proportion of the effect of obesity
276 than suggested by previous conventional observational analyses⁽¹⁵⁾.

277 Also of relevance here, we considered genetic liability to diabetes and genetically predicted fasting
278 glucose in non-diabetic individuals as separate risk factors. Our findings support the concept that
279 obesity traits confer an increased risk of CVD specifically through liability to diabetes, rather than
280 variation in fasting glucose levels within the normal physiological range. This is important because
281 fasting glucose may have a non-linear association with CVD risk(50), only having detrimental effects
282 beyond a certain point(51).

283 Our current study also has limitations. The genetic association data used in this work are drawn from
284 predominantly European populations, and should therefore be interpreted with caution when
285 extrapolating to other ethnic groups. Diabetes is a binary outcome, and as such our consideration of
286 genetically predicted diabetes could introduce bias into the mediation analysis because not all
287 individuals possessing such genetic liability develop diabetes-related traits(38). SBP was used as a
288 proxy for studying the effects of blood pressure more generally. Given the high degree of phenotypic
289 and genetic correlation between blood pressure traits(52), this would seem unlikely to affect the
290 conclusions drawn. A theoretical weakness of the MR approach relates to bias from pleiotropic
291 effects of the genetic variants incorporated as instruments for the traits under study, whereby they
292 may directly affect the outcome through pathways independent of the exposure or mediators being
293 considered. Although such bias cannot be entirely excluded, it is reassuring that we obtained similar
294 MR estimates for the total effect of BMI and WHR respectively on the three CVD outcomes when
295 performing the IVW, contamination-mixture and weighted median MR methods that each make
296 different assumptions concerning the presence of pleiotropic variants(53). Finally, there is currently
297 no available method for assessing instrument strength within the two-sample multivariable MR
298 setting, and we could therefore not assess potential vulnerability to weak instrument bias(35).

In conclusion, this work using the MR framework suggests that the majority of the effects of obesity on CVD risk are mediated through metabolic risk factors, most notably diabetes and blood pressure. Comprehensive public health measures that target the reduction of obesity prevalence alongside control and management of its downstream mediators are likely to be most effective for minimizing the burden of obesity on individuals and health systems alike.

References

1. GBD. Global, regional, and national age-sex specific mortality for 264 causes of death, 1980-2016: a systematic analysis for the Global Burden of Disease Study 2016. *Lancet*. 2017;390(10100):1151-210.
2. Singh GM, Danaei G, Farzadfar F, Stevens GA, Woodward M, Wormser D, et al. The age-specific quantitative effects of metabolic risk factors on cardiovascular diseases and diabetes: a pooled analysis. *PLoS One*. 2013;8(7):e65174.
3. Van Gaal LF, Mertens IL, De Block CE. Mechanisms linking obesity with cardiovascular disease. *Nature*. 2006;444(7121):875-80.
4. Carreras-Torres R, Johansson M, Haycock PC, Relton CL, Davey Smith G, Brennan P, et al. Role of obesity in smoking behaviour: Mendelian randomisation study in UK Biobank. *BMJ*. 2018;361:k1767.
5. Taylor AE, Richmond RC, Palviainen T, Loukola A, Wootton RE, Kaprio J, et al. The effect of body mass index on smoking behaviour and nicotine metabolism: a Mendelian randomization study. *Hum Mol Genet*. 2019;28(8):1322-30.
6. Jaacks LM, Vandevijvere S, Pan A, McGowan CJ, Wallace C, Imamura F, et al. The obesity transition: stages of the global epidemic. *Lancet Diabetes Endocrinol*. 2019;7(3):231-40.
7. Ward ZJ, Bleich SN, Cradock AL, Barrett JL, Giles CM, Flax C, et al. Projected U.S. State-Level Prevalence of Adult Obesity and Severe Obesity. *N Engl J Med*. 2019;381(25):2440-50.

- 324 8. Wright JM, Musini VM, Gill R. First-line drugs for hypertension. Cochrane Database Syst Rev.
325 2018;4:CD001841.
- 326 9. Michos ED, McEvoy JW, Blumenthal RS. Lipid Management for the Prevention of
327 Atherosclerotic Cardiovascular Disease. N Engl J Med. 2019;381(16):1557-67.
- 328 10. Rigotti NA, Clair C. Managing tobacco use: the neglected cardiovascular disease risk factor.
329 Eur Heart J. 2013;34(42):3259-67.
- 330 11. Davies MJ, D'Alessio DA, Fradkin J, Kernan WN, Mathieu C, Mingrone G, et al. Management
331 of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes
332 Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care.
333 2018;41(12):2669-701.
- 334 12. Neeland IJ, Ross R, Despres JP, Matsuzawa Y, Yamashita S, Shai I, et al. Visceral and ectopic
335 fat, atherosclerosis, and cardiometabolic disease: a position statement. Lancet Diabetes Endocrinol.
336 2019;7(9):715-25.
- 337 13. Chen GC, Arthur R, Iyengar NM, Kamensky V, Xue XN, Wassertheil-Smoller S, et al.
338 Association between regional body fat and cardiovascular disease risk among postmenopausal
339 women with normal body mass index. Eur Heart J. 2019;40(34):2849-+.
- 340 14. Sahakyan KR, Somers VK, Rodriguez-Escudero JP, Hodge DO, Carter RE, Sochor O, et al.
341 Normal-Weight Central Obesity: Implications for Total and Cardiovascular Mortality. Ann Intern
342 Med. 2015;163(11):827-35.
- 343 15. Lu Y, Hajifathalian K, Ezzati M, Woodward M, Rimm EB, Danaei G, et al. Metabolic mediators
344 of the effects of body-mass index, overweight, and obesity on coronary heart disease and stroke: a
345 pooled analysis of 97 prospective cohorts with 1.8 million participants. Lancet. 2014;383(9921):970-
346 83.
- 347 16. Carter AR, Sanderson E, Hammerton G, Richmond RC, Smith GD, Heron J, et al. Mendelian
348 randomisation for mediation analysis: current methods and challenges for implementation. bioRxiv.
349 2019:835819.

- 350 17. Relton CL, Davey Smith G. Two-step epigenetic Mendelian randomization: a strategy for
351 establishing the causal role of epigenetic processes in pathways to disease. *Int J Epidemiol*.
352 2012;41(1):161-76.
- 353 18. Burgess S, Thompson DJ, Rees JMB, Day FR, Perry JR, Ong KK. Dissecting Causal Pathways
354 Using Mendelian Randomization with Summarized Genetic Data: Application to Age at Menarche
355 and Risk of Breast Cancer. *Genetics*. 2017;207(2):481-7.
- 356 19. Davey Smith G, Davies NM, Dimou N, Egger M, Gallo V, Golub R, et al. STROBE-MR:
357 Guidelines for strengthening the reporting of Mendelian randomization studies.
358 <https://doi.org/10.7287/peerj.preprints.27857v1>. *PeerJ Preprints*. 2019;7:e27857v1.
- 359 20. Pulit SL, Stoneman C, Morris AP, Wood AR, Glastonbury CA, Tyrrell J, et al. Meta-analysis of
360 genome-wide association studies for body fat distribution in 694 649 individuals of European
361 ancestry. *Hum Mol Genet*. 2019;28(1):166-74.
- 362 21. Carter AR, Gill D, Davies NM, Taylor AE, Tillmann T, Vaucher J, et al. Understanding the
363 consequences of education inequality on cardiovascular disease: mendelian randomisation study.
364 *BMJ*. 2019;365:l1855.
- 365 22. Wootton RE, Richmond RC, Stuijzand BG, Lawn RB, Sallis HM, Taylor GMJ, et al. Evidence for
366 causal effects of lifetime smoking on risk for depression and schizophrenia: a Mendelian
367 randomisation study. *Psychol Med*. 2019:1-9.
- 368 23. Mahajan A, Taliun D, Thurner M, Robertson NR, Torres JM, Rayner NW, et al. Fine-mapping
369 type 2 diabetes loci to single-variant resolution using high-density imputation and islet-specific
370 epigenome maps. *Nat Genet*. 2018;50(11):1505-13.
- 371 24. Fasting glucose and insulin variability: sex-dimorphic genetic effects and novel loci Vasiliki
372 Lagou, Reedik Mägi, Jouke-Jan J Hottenga, et al. (2019) IN PREPARATION .
- 373 25. Purcell S, Neale B, Todd-Brown K, Thomas L, Ferreira MA, Bender D, et al. PLINK: a tool set
374 for whole-genome association and population-based linkage analyses. *Am J Hum Genet*.
375 2007;81(3):559-75.

376 26. Willer CJ, Schmidt EM, Sengupta S, Peloso GM, Gustafsson S, Kanoni S, et al. Discovery and
377 refinement of loci associated with lipid levels. *Nat Genet.* 2013;45(11):1274-83.

378 27. Nikpay M, Goel A, Won HH, Hall LM, Willenborg C, Kanoni S, et al. A comprehensive 1,000
379 Genomes-based genome-wide association meta-analysis of coronary artery disease. *Nat Genet.*
380 2015;47(10):1121-30.

381 28. Klarin D, Lynch J, Aragam K, Chaffin M, Assimes TL, Huang J, et al. Genome-wide association
382 study of peripheral artery disease in the Million Veteran Program. *Nat Med.* 2019;25(8):1274-9.

383 29. Malik R, Chauhan G, Traylor M, Sargurupremraj M, Okada Y, Mishra A, et al. Multiancestry
384 genome-wide association study of 520,000 subjects identifies 32 loci associated with stroke and
385 stroke subtypes. *Nat Genet.* 2018;50(4):524-37.

386 30. Hemani G, Zheng J, Elsworth B, Wade KH, Haberland V, Baird D, et al. The MR-Base platform
387 supports systematic causal inference across the human phenome. *eLife.* 2018;7.

388 31. Burgess S, Butterworth A, Thompson SG. Mendelian randomization analysis with multiple
389 genetic variants using summarized data. *Genet Epidemiol.* 2013;37(7):658-65.

390 32. Bowden J, Davey Smith G, Haycock PC, Burgess S. Consistent Estimation in Mendelian
391 Randomization with Some Invalid Instruments Using a Weighted Median Estimator. *Genet*
392 *Epidemiol.* 2016;40(4):304-14.

393 33. Burgess S, Foley CN, Allara E, Staley JR, Howson JMM. A robust and efficient method for
394 Mendelian randomization with hundreds of genetic variants. *Nat Commun.* 2020;11(1):376.

395 34. Yavorska OO, Burgess S. MendelianRandomization: an R package for performing Mendelian
396 randomization analyses using summarized data. *Int J Epidemiol.* 2017;46(6):1734-9.

397 35. Sanderson E, Davey Smith G, Windmeijer F, Bowden J. An examination of multivariable
398 Mendelian randomization in the single-sample and two-sample summary data settings. *Int J*
399 *Epidemiol* 2018;48(3):713-27.

400 36. Burgess S, Thompson SG. Multivariable Mendelian randomization: the use of pleiotropic
401 genetic variants to estimate causal effects. *Am J Epidemiol.* 2015;181(4):251-60.

402 37. Burgess S, Dudbridge F, Thompson SG. Re: "Multivariable Mendelian randomization: the use
403 of pleiotropic genetic variants to estimate causal effects". Am J Epidemiol. 2015;181(4):290-1.

404 38. Burgess S, Labrecque JA. Mendelian randomization with a binary exposure variable:
405 interpretation and presentation of causal estimates. Eur J Epidemiol. 2018;33(10):947-52.

406 39. Douketis JD, Macie C, Thabane L, Williamson DF. Systematic review of long-term weight loss
407 studies in obese adults: clinical significance and applicability to clinical practice. Int J Obes (Lond).
408 2005;29(10):1153-67.

409 40. Rucker D, Padwal R, Li SK, Curioni C, Lau DC. Long term pharmacotherapy for obesity and
410 overweight: updated meta-analysis. BMJ. 2007;335(7631):1194-9.

411 41. Buchwald H, Avidor Y, Braunwald E, Jensen MD, Pories W, Fahrbach K, et al. Bariatric
412 surgery: a systematic review and meta-analysis. JAMA. 2004;292(14):1724-37.

413 42. NCD Risk Factor Collaboration. Trends in adult body-mass index in 200 countries from 1975
414 to 2014: a pooled analysis of 1698 population-based measurement studies with 19.2 million
415 participants. Lancet. 2016;387(10026):1377-96.

416 43. Foreman KJ, Marquez N, Dolgert A, Fukutaki K, Fullman N, McGaughey M, et al. Forecasting
417 life expectancy, years of life lost, and all-cause and cause-specific mortality for 250 causes of death:
418 reference and alternative scenarios for 2016-40 for 195 countries and territories. Lancet.
419 2018;392(10159):2052-90.

420 44. Pearson-Stuttard J, Ezzati M, Gregg EW. Multimorbidity-a defining challenge for health
421 systems. Lancet Public Health. 2019;4(12):e599-e600.

422 45. Caleyachetty R, Thomas GN, Toulis KA, Mohammed N, Gokhale KM, Balachandran K, et al.
423 Metabolically Healthy Obese and Incident Cardiovascular Disease Events Among 3.5 Million Men and
424 Women. J Am Coll Cardiol. 2017;70(12):1429-37.

425 46. Backholer K, Beauchamp A, Ball K, Turrell G, Martin J, Woods J, et al. A framework for
426 evaluating the impact of obesity prevention strategies on socioeconomic inequalities in weight. Am J
427 Public Health. 2014;104(10):e43-50.

- 428 47. Adams J, Mytton O, White M, Monsivais P. Why Are Some Population Interventions for Diet
429 and Obesity More Equitable and Effective Than Others? The Role of Individual Agency. PLoS
430 Medicine. 2016;13(4).
- 431 48. Lawlor DA, Tilling K, Davey Smith G. Triangulation in aetiological epidemiology. Int J
432 Epidemiol. 2016;45(6):1866-86.
- 433 49. Xu L, Borges MC, Hemani G, Lawlor DA. The role of glycaemic and lipid risk factors in
434 mediating the effect of BMI on coronary heart disease: a two-step, two-sample Mendelian
435 randomisation study. Diabetologia. 2017;60(11):2210-20.
- 436 50. Park C, Guallar E, Linton JA, Lee DC, Jang Y, Son DK, et al. Fasting glucose level and the risk of
437 incident atherosclerotic cardiovascular diseases. Diabetes Care. 2013;36(7):1988-93.
- 438 51. Fuller JH, Shipley MJ, Rose G, Jarrett RJ, Keen H. Coronary-heart-disease risk and impaired
439 glucose tolerance. The Whitehall study. Lancet. 1980;1(8183):1373-6.
- 440 52. Evangelou E, Warren HR, Mosen-Ansorena D, Mifsud B, Pazoki R, Gao H, et al. Genetic
441 analysis of over 1 million people identifies 535 new loci associated with blood pressure traits. Nat
442 Genet. 2018;50(10):1412-25.
- 443 53. Slob EAW, Burgess S. A Comparison Of Robust Mendelian Randomization Methods Using
444 Summary Data. bioRxiv. 2019:577940.

445

446 **Author contributions**

447 DG, JD, KKT, SMD and SB designed the project. DK, PST, SMD and VA-MVP provided data. DG and VZ
448 analysed the data. DG, JD and JP-S drafted the manuscript. All authors interpreted the results and
449 critically revised the manuscript. All authors approved the submitted article. All authors are
450 accountable for the integrity of the research.

451

Conflicts of interest

DG is a part-time employee of Novo Nordisk. JP-S reports personal fees from Novo Nordisk related to consultancy outside of the submitted work. All other authors have no conflicts of interest to declare.

Sources of Funding

This work was supported by funding from the US Department of Veterans Affairs Office of Research and Development, Million Veteran Program Grant MVP003 (I01-BX003362). This publication does not represent the views of the Department of Veterans Affairs of the US Government. The MEGASTROKE project received funding from sources specified at <http://www.megastroke.org/acknowledgments.html>. Details of all MEGASTROKE authors are available at <http://www.megastroke.org/authors.html>. This work was supported by the National Institute for Health Research (NIHR) Biomedical Research Centre at the University Hospitals Bristol National Health Service (NHS) Foundation Trust and the University of Bristol. The views expressed in this publication are those of the authors and not necessarily those of the NHS, the NIHR or the Department of Health and Social Care. DG and JP-S are funded by the Wellcome 4i Clinical PhD Program at Imperial College London (203928/Z/16/Z). ARC and ES are funded by and work in a unit that receives core funding from the Medical Research Council (MRC) and University of Bristol (MC_UU00011/1). VK is funded by the European Union's Horizon 2020 research and innovation program under the Marie Skłodowska-Curie grant (721567). REW is a member of the MRC Integrative Epidemiology Unit at the University of Bristol funded by the MRC (MC_UU_00011/7). SMD was supported by the Department of Veterans Affairs Office of Research and Development (IK2-CX001780). SB is supported by Sir Henry Dale Fellowship jointly funded by the Wellcome Trust and the Royal Society (204623/Z/16/Z). PE acknowledges support from the MRC (MR/S019669/1), the NIHR Imperial Biomedical Research Centre, Imperial College London (RDF03), the UK Dementia Research Institute (DRI) at Imperial College London funded by UK DRI Ltd (funded by MRC,

Alzheimer's Society, Alzheimer's Research UK), and Health Data Research (HDR) UK London funded by HDR UK Ltd (funded by a consortium led by the MRC 1004231). The funding sources for this work were not involved in study design, data analysis, interpretation of results or writing of the manuscript.

Acknowledgements

The authors acknowledge the contributors of the data used in this work: CARDIoGRAMplusC4D, DIAGRAM, GIANT, Global Lipids Genetics Consortium, MAGIC, MEGASTROKE, Million Veterans Program and UK Biobank.





Figure legends

Figure 1. Total effects of genetically predicted body mass index (BMI) and genetically predicted waist-to-hip ratio (WHR) on coronary artery disease (CAD), peripheral artery disease (PAD) and stroke. Inverse-variance weighted (IVW), contamination-mixture method (Con-Mix) and weighted median (Median) represent distinct Mendelian randomization approaches that differ in their requisite assumptions. CI: confidence interval; IVW: inverse-variance weighted; OR: odds ratio; SD: standard deviation.

Figure 2. Direct effects of genetically predicted body mass index (BMI) and genetically predicted waist-to-hip ratio (WHR) on coronary artery disease (CAD), peripheral artery disease (PAD) and stroke, estimated after adjusting for genetic liability to mediators separately and together in the same model. The y-axis details the genetically predicted mediator(s) for which adjusted was made. Blood pressure relates to systolic blood pressure. Lipids relates to serum low-density lipoprotein cholesterol, high-density lipoprotein cholesterol and triglycerides considered together in one model. CI: confidence interval; OR: odds ratio; SD: standard deviation.







501 **Figure 3. Direct effects of body mass index (BMI) and waist-to-hip ratio (WHR) on coronary artery**
 502 **disease (CAD), peripheral artery disease (PAD) and stroke, estimated after no adjustment and**
 503 **after adjustment for genetically predicted fasting glucose in non-diabetics. CI: confidence interval;**
 504 **OR: odds ratio; SD: standard deviation.**

505 **Figure 4. Direct effects of genetically predicted body mass index (BMI) and genetically predicted**
 506 **waist-to-hip ratio (WHR) on coronary artery disease (CAD), peripheral artery disease (PAD) and**
 507 **stroke, estimated after adjusting for each other. CI: confidence interval; OR: odds ratio; SD:**
 508 **standard deviation.**



OR per 1-SD increase in BMI (95% CI)

OR per 1-SD increase in WHR (95% CI)



OR per 1-SD increase in BMI (95% CI)

OR per 1-SD increase in WHR (95% CI)

